Idorsia AG

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
  • TickerA2DTEB
  • ISINCH0363463438
  • ExchangeSix Swiss Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySwitzerland

Analysts

Despite a better risk assessment and improving to Slightly Negative, IDORSIA LIMITED remains under pressure

IDORSIA LIMITED (CH), a company active in the Biotechnology industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 2 out of 4 possible stars; the general evaluation is slightly increased to Slightly Negative but the title remains under pressure. As of the analysis date May 14, 2019, the closing price was CHF 21.22 and its target price was estimated at CHF 15.51.

Expert Corporate Governance Service (ECGS)

Idorsia - AGM 03 May 2019

ITEM 1.2 - Advisory vote on the remuneration report. The transparency of the remuneration report is insufficient. The remuneration report is not in line with Ethos' guidelines. Ethos recommends to OPPOSE. ITEM 4 - Approve renewal and increase of authorised capital. The requested authority to issue shares, without tradable pre-emptive rights, for general financing purposes, exceeds 15% of the issued capital. In case of approval of the request, the aggregate of all authorities to issue shares without tradable pre-emptive rights for general financing purposes would exceed 20% of the issued share...

1 director bought

A director at Idorsia Ltd bought 3,388,015 shares at 25.620CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

IDIA SW, Updated Analysis, Strong Pipeline Plus Cash for Spinoff, +29% Upside

Strong Pipeline and Loaded with Cash, Idorsia (IDIA) is Ready to Become a Second Actelion (ATLN) For the Parent, Stay on the Sidelines from ATLN (Pre-Spin) Due to Limited Upside Spinoff: Investors Recommended to Enter IDIA (Post-Spin) Near CHF7.00 Levels / First Day of Trading June 16, 2017 Upside (From Tech Split Price): +29% (Base) & +77% (Bull) Experienced Management Team, Including CEO Jean-Paul Clozel, Moves to IDIA JNJ's Investment in IDIA Reflects Its Confidence in the Spinoff's Drug Pipeline The Edge Awaits Spinoff Listing to Evaluate Entry / On Watchlist

IDIA SW, Updated Analysis, Strong Pipeline Plus Cash for Spinoff, +29% Upside

Strong Pipeline and Loaded with Cash, Idorsia (IDIA) is Ready to Become a Second Actelion (ATLN) For the Parent, Stay on the Sidelines from ATLN (Pre-Spin) Due to Limited Upside Spinoff: Investors Recommended to Enter IDIA (Post-Spin) Near CHF7.00 Levels / First Day of Trading June 16, 2017 Upside (From Tech Split Price): +29% (Base) & +77% (Bull) Experienced Management Team, Including CEO Jean-Paul Clozel, Moves to IDIA JNJ's Investment in IDIA Reflects Its Confidence in the Spinoff's Drug Pipeline The Edge Awaits Spinoff Listing to Evaluate Entry / On Watchlist

1 director bought

A director at Idorsia Ltd bought 3,388,015 shares at 25.620CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...

Despite a better risk assessment and improving to Slightly Negative, IDORSIA LIMITED remains under pressure

IDORSIA LIMITED (CH), a company active in the Biotechnology industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 2 out of 4 possible stars; the general evaluation is slightly increased to Slightly Negative but the title remains under pressure. As of the analysis date May 14, 2019, the closing price was CHF 21.22 and its target price was estimated at CHF 15.51.

Expert Corporate Governance Service (ECGS)

Idorsia - AGM 03 May 2019

ITEM 1.2 - Advisory vote on the remuneration report. The transparency of the remuneration report is insufficient. The remuneration report is not in line with Ethos' guidelines. Ethos recommends to OPPOSE. ITEM 4 - Approve renewal and increase of authorised capital. The requested authority to issue shares, without tradable pre-emptive rights, for general financing purposes, exceeds 15% of the issued capital. In case of approval of the request, the aggregate of all authorities to issue shares without tradable pre-emptive rights for general financing purposes would exceed 20% of the issued share...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch